Sutro Biopharma (STRO) Preferred Stock Liabilities (2016 - 2018)

Sutro Biopharma has reported Preferred Stock Liabilities for 3 years, with the latest figure at $187.2 million in Q3 2018.

• Quarterly Preferred Stock Liabilities changed N/A year-over-year to $187.2 million in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $187.2 million (changed N/A YoY) and the FY2017 annual result came in at $102.5 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities advanced to $187.2 million in Q3 2018 per STRO's latest filing, from $102.5 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $187.2 million in Q3 2018 and troughed at $102.5 million in Q4 2016.
• A 3-year average of $130.8 million and a median of $102.5 million in 2016 frame the typical range for Preferred Stock Liabilities.
• The widest YoY moves for Preferred Stock Liabilities: up 0.0% in 2017, down 0.0% in 2017.
• Over 3 years, Preferred Stock Liabilities stood at $102.5 million in 2016, then changed by 0.0% to $102.5 million in 2017, then soared by 82.67% to $187.2 million in 2018.
• According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $187.2 million, $102.5 million, and $102.5 million for Q3 2018, Q4 2017, and Q4 2016 respectively.